Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07493447 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
A Early Phase 1 study, sponsored by Eben Rosenthal.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT07493447 is a Early Phase 1 study that is actively recruiting participants, run by Eben Rosenthal. The registered enrollment target is 30 participants.
The verdict
NCT07493447, a Early Phase 1 study, is actively recruiting participants, sponsored by Eben Rosenthal.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
Interventions
- DRUG Panitumumab-IRDye800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-07 |
| Est. Completion | 2031-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07493447
The ClinicalTrials.gov registry entry for NCT07493447 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Panitumumab-IRDye800 is the first listed.
NCT07493447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07493447 about?
NCT07493447 is a clinical study titled "Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures". This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
What is the current status of trial NCT07493447?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2026-07. Estimated completion is 2031-06.
What interventions are being tested in trial NCT07493447?
The interventions under investigation include: Panitumumab-IRDye800 (DRUG).
Who is sponsoring clinical trial NCT07493447?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.